ITRAQ-based quantitative proteomic analysis for identification of oligodendroglioma biomarkers related with loss of heterozygosity on chromosomal arm 1p

Journal of Proteomics

Volumn 77, Issue , 2012, Pages 480-491

  Yang, Liu song ^a   Xu, Xiao en ^b   Liu, Xiu ping ^b   Jin, Hong ^b   Chen, Zhong qing ^a   Liu, Xiao hui ^b   Wang, Yin ^a   Huang, Feng ping ^a   Shi, Qian ^b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

1p LOH; Biomarkers; FISH; ITRAQ; Oligodendroglioma; Proteomics

Indexed keywords

ADENOSINE TRIPHOSPHATASE; BIOLOGICAL MARKER; HIGH MOBILITY GROUP B1 PROTEIN; MICROTUBULE ASSOCIATED PROTEIN 2; UBIQUITIN; UBIQUITIN LIKE MODIFIER ACTIVATING ENZYME 1; UNCLASSIFIED DRUG;

ACTIN FILAMENT; ARTICLE; CHROMOSOME 1P; CLINICAL ARTICLE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISOBARIC TAGS FOR RELATIVE AND ABSOLUTE QUANTIFICATION; LIQUID CHROMATOGRAPHY; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEOMICS; TANDEM MASS SPECTROMETRY;

BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; NEOPLASM PROTEINS; NERVE TISSUE PROTEINS; OLIGODENDROGLIOMA; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84870388293     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.09.028     Document Type: Article

References (34)

1. Engelhard H.H., Stelea A., Cochran E.J. Oligodendroglioma: pathology and molecular biology. Surg Neurol 2002, 58:111-117. [discussion 117].
2. Engelhard H.H., Stelea A., Mundt A. Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. Surg Neurol 2003, 60:443-456.
3. Kros J.M., Gorlia T., Kouwenhoven M.C., Zheng P.P., Collins V.P., Figarella-Branger D., et al. Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol 2007, 66:545-551.
4. Reifenberger G., Louis D.N. Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 2003, 62:111-126.
5. Smith J.S., Perry A., Borell T.J., Lee H.K., O'Fallon J., Hosek S.M., et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000, 18:636-645.
6. Grzendowski M., Wolter M., Riemenschneider M.J., Knobbe C.B., Schlegel U., Meyer H.E., et al. Differential proteome analysis of human gliomas stratified for loss of heterozygosity on chromosomal arms 1p and 19q. Neuro Oncol 2010, 12:243-256.
7. Iwadate Y., Sakaida T., Hiwasa T., Nagai Y., Ishikura H., Takiguchi M., et al. Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res 2004, 64:2496-2501.
8. Furuta M., Weil R.J., Vortmeyer A.O., Huang S., Lei J., Huang T.N., et al. Protein patterns and proteins that identify subtypes of glioblastoma multiforme. Oncogene 2004, 23:6806-6814.
9. Unwin R.D., Evans C.A., Whetton A.D. Relative quantification in proteomics: new approaches for biochemistry. Trends Biochem Sci 2006, 31:473-484.
10. Camp N.J., Slattery M.L. Classification tree analysis: a statistical tool to investigate risk factors interactions with an example for colon cancer (United States). Cancer Causes Control 2001, 13:813-823.
11. Xu X., Qiao M., Zhang Y., Jiang Y., Wei P., Yao J., et al. Quantitative proteomics study of breast cancer cell lines isolated from a single patient: discovery of TIMM17A as a marker for breast cancer. Proteomics 2010, 10:1374-1390.
12. Perathoner A., Pirkebner D., Brandacher G., Spizzo G., Stadlmann S., Obrist P., et al. 14-3-3sigma expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Clin Cancer Res 2005, 11:3274-3279.
13. Matta A., DeSouza L.V., Shukla N.K., Gupta S.D., Ralhan R., Siu K.W. Prognostic significance of head-and-neck cancer biomarkers previously discovered and identified using iTRAQ-labeling and multidimensional liquid chromatography-tandem mass spectrometry. J Proteome Res 2008, 7:2078-2087.
14. Husemann K., Wolter M., Buschges R., Bostrom J., Sabel M., Reifenberger G. Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors. J Neuropathol Exp Neurol 1999, 58:1041-1050.
15. Mai M., Huang H., Reed C., Qian C., Smith J.S., Alderete B., et al. Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions. Genomics 1998, 51:359-363.
16. French P.J., Swagemakers S.M., Nagel J.H., Kouwenhoven M.C., Brouwer E., van der Spek P., et al. Gene expression profiles associated with treatment response in oligodendrogliomas. Cancer Res 2005, 65:11335-11344.
17. Mukasa A., Ueki K., Matsumoto S., Tsutsumi S., Nishikawa R., Fujimaki T., et al. Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p. Oncogene 2002, 21:3961-3968.
18. Okamoto H., Li J., Glasker S., Vortmeyer A.O., Jaffe H., Robison R.A., et al. Proteomic comparison of oligodendrogliomas with and without 1pLOH. Cancer Biol Ther 2007, 6:391-396.
19. Rostomily R.C., Born D.E., Beyer R.P., Jin J., Alvord E.C., Mikheev A.M., et al. Quantitative proteomic analysis of oligodendrogliomas with and without 1p/19q deletion. J Proteome Res 2010, 9:2610-2618.
20. Garbis S.D., Tyritzis S.I., Roumeliotis T., Zerefos P., Giannopoulou E.G., Vlahou A., et al. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry. J Proteome Res 2008, 7:3146-3158.
21. Su Z.L., Mo X.L., Feng Z.Y., Lin H.L., Ding Y.G. UBE1 expression in extranodal NK/T cell lymphoma, nasal type. Leuk Lymphoma 2008, 49:1821-1822.
22. Mani A., Gelmann E.P. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005, 23:4776-4789.
23. Ellerman J.E., Brown C.K., de Vera M., Zeh H.J., Billiar T., Rubartelli A., et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 2007, 13:2836-2848.
24. Zhu S., Li W., Ward M.F., Sama A.E., Wang H. High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation. Inflamm Allergy Drug Targets 2010, 9:60-72.
25. Kepp O., Tesniere A., Schlemmer F., Michaud M., Senovilla L., Zitvogel L., et al. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 2009, 14:364-375.
26. Tatard V.M., Xiang C., Biegel J.A., Dahmane N. ZNF238 is expressed in postmitotic brain cells and inhibits brain tumor growth. Cancer Res 2010, 70:1236-1246.
27. Veitia R., David S., Barbier P., Vantard M., Gounon P., Bissery M.C., et al. Proteolysis of microtubule associated protein 2 and sensitivity of pancreatic tumours to docetaxel. Br J Cancer 2000, 83:544-549.
28. Bauer J.A., Chakravarthy A.B., Rosenbluth J.M., Mi D., Seeley E.H., De Matos Granja-Ingram N., et al. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res 2010, 16:681-690.
29. Schmidt A., Hall M.N. Signaling to the actin cytoskeleton. Annu Rev Cell Dev Biol 1998, 14:305-338.
30. Li S., Yan C., Huang L., Qiu X., Wang Z., Jiang T. Molecular prognostic factors of anaplastic oligodendroglia tumors and its relationship: a single institutional review of 77 patients from China. Neuro Oncol 2012, 14:109-116.
31. Yip S., Butterfield Y.S., Morozova O., Chittaranjan S., Blough M.D., An J., et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 2012, 226:7-16.
32. Sahm F., Koelsche C., Meyer J., Pusch S., Lindenberg K., Mueller W., et al. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathol 2012, 123:853-860.
33. Bettegowda C., Agrawal N., Jiao Y., Sausen M., Wood L.D., Hruban R.H., et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 2011, 333:1453-1455.
34. Blough M.D., Al-Najjar M., Chesnelong C., Binding C.E., Rogers A.D., Luchman H.A., et al. DNA hypermethylation and 1p loss silence NHE-1 in oligodendroglioma. Ann Neurol 2012, 71:845-849.